Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | AB INBEV | 2 | 30 | -1,79 % | |
| GBL | 1 | 1 | -1,35 % | |
| SOLVAY | 1 | - | -1,86 % | |
| UCB | 1 | - | -4,11 % | |
| ARGENX | - | 10 | -2,96 % | ||
| MELEXIS | - | 4 | +2,84 % | |
| ELIA GROUP | - | 4 | -0,79 % | |
| UMICORE | - | 2 | +0,06 % | |
| AGEAS | - | 1 | +0,51 % | |
| KBC GROEP NV | - | 1 | +0,08 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:58 | Solvay S.A.: Participation notification by Citigroup Inc. | 126 | GlobeNewswire (Europe) | Press release Regulated information
Brussels, April 21, 2026, 17:45 CEST
In line with Belgian transparency legislation (Law... ► Artikel lesen | |
| 14:10 | UCB partners with Myasthenia Gravis Foundation of America on meal program targeting nutrition deserts | 1 | FiercePharma | ||
| 10:38 | ANHEUSER-BUSCH INBEV SA/NV: Ruhe vor der nächsten Bewegung | 7 | Maximilian Berger | ||
| 06:38 | Why BlackRock's investment in Anheuser-Busch InBev didn't shake the market | 20 | IOL | ||
| Mo | GBL: GBL - Transactions on GBL shares 20-04-2026 | 1 | Euronext | ||
| Mo | Interview with Laurein Cornelissen, Team Lead Expertise Power Transformers at Elia | 3 | Transformers | ||
| Mo | BERNSTEIN RESEARCH stuft AB Inbev auf 'Outperform' | 566 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für AB Inbev von 83 auf 87 Euro angehoben und die Einstufung auf "Outperform" belassen. Trevor Stirling zog in einer... ► Artikel lesen | |
| Mo | UCB Proposes $650M Acquisition of Neurona Therapeutics | 5 | Contract Pharma | ||
| Mo | UCB to purchase Neurona and NRTX-1001 for $1.15bn | 1 | Pharmaceutical Technology | ||
| Mo | UCB cuts $1.15bn deal to buy epilepsy biotech Neurona | 4 | pharmaphorum | ||
| Mo | ARGENX SE - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | Italy's private equity weekly roundup. News from BeBeez, Di Luccia & Partners, Banca Investis, Duke&Kay, Recordati, CVC, Groupe Bruxelles Lambert, Adia, Gic, Caisse de Depot et Placement du Quebec, and more | 5 | BeBeez | ||
| Mo | KBC Groep: Notification for bondholders of KBC IFIMA | 240 | GlobeNewswire (Europe) | Following document is available on www.kbc.com:
- 2025 financial report of KBC IFIMA
► Artikel lesen | |
| Mo | ANHEUSER-BUSCH INBEV SA/NV - Disclosure Made According to the Requirements of the Law of 2 May 2007 | 4 | SENS | ||
| Sa | Should Altria sell off its Anheuser-Bush InBev stake? It's complicated | 46 | Seeking Alpha | ||
| Sa | argenx SE: argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP | 4 | GlobeNewswire (USA) | ||
| Fr | UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B | 2 | BioPharma Dive | ||
| Fr | Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B | 4 | Seeking Alpha | ||
| Fr | UCB übernimmt Neurona Therapeutics für bis zu 1,15 Milliarden US-Dollar | 2 | Investing.com Deutsch | ||
| Fr | UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine | 12 | FierceBiotech |
1 2 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.